Skip to main content

"We've detected that you're visiting from {0}. Would you like to switch languages for tailored content?"

->

Surgical skin preparation

SSI prevention: Stronger together 

You're on the front lines in the fight against healthcare-associated infections (HAIs), and as your partner, we're here to support you with science-based solutions and a holistic approach to risk reduction. Collaborating with clinical experts, we developed a suite of solutions to support you in your effort to reduce the risk of SSIs. 

We know that: 

$68K

A single SSI can cost up to an additional $68K1 per patient.

Email Icon - An iconographic representation of a person with an IV bag with a cross on it to signify a patient.

$45K

The average CLABSI can cost $45K2 per incident.

An iconographic representation of medical cost to treat CRBSI with a medical cross and us dollar sign. Dark green and teal positive color palette.

30%

30% of patients are already colonized with S. aureus.3

An iconographic representation of germs in a no symbol to represent antimicrobial protection. IV green and dark green positive color palette. POS SVG

80%

Approximately 80% of SSIs from S. aureus come from the patient's own nasal flora.4-6

An iconographic representation of a sick patient paired with a representation of bacteria. Dark green and medium teal positive color palette.

3M Skin and Nasal Antiseptic

Reduce the risk of SSIs by reducing bacteria in the nares with 3M™ Skin and Nasal Antiseptic (Povidone-Iodine Solution 5% w/w [0.5% available iodine] USP) Patient Preoperative Skin Preparation.

  • 80% of SSIs from S. aureus come from the patient’s own nasal flora,4-6 making it a significant risk factor for developing an SSI
  • Skin and Nasal Antiseptic helps reduce SSIs when part of a comprehensive preoperative protocol

Follow guidelines and practices by leading organizations to help decrease the risk of SSIs.

Explore solutions
Skin and Nasal Antiseptic Bottle and Applicators, white background, product photo, cmyk, tiff, 70-2010-8268-5, 70-2010-8271-9, 70-2010-8272-7, 70-2010-8274-3, 70-2010-8275-0, 70-2010-8277-6, 70-2010-8278-4, 70-2010-8380-8, 70-2010-8378-2, 70-2010-8379-0, 70-2010-8375-8, 70-2010-8374-1, 70-2010-8399-8

3M SoluPrep S Sterile Antiseptic Solution

Skin prep with efficacy you can depend on - 3M™ SoluPrep™ S Sterile Antiseptic Solution chlorhexidine gluconate (2% w/v) and isopropyl alcohol (70% v/v) Patient Preoperative Skin Preparation.

  • Provides fast-acting, broad-spectrum antimicrobial activity (in vitro)*, and persistence for at least 10 days post-prep, as shown in a study of healthy volunteers**
  • Helps reduce bacteria that can cause skin infections.
  • 52% reduction in drape lift through enhanced incise drape adherence.1
  • 60% more coverage area when using a 26mL applicator.2

 

SoluPrep S Sterile Antiseptic Solution provides added benefit for preparing patients' skin before surgery, providing safety and protection against potential skin infections.


1. Compared to skin prepped with ChloraPrep® with 3MTM IobanTM 2 Antimicrobial Incise Drapes in a simulated knee surgery model, 2019.
2. Compared to ChloraPrep® Surgical Prep, 2021.

*The clinical significance of in vitro data is unknown. ​
**Evaluated persistence per the 2015 Healthcare Antiseptics Tentative Final Monograph criteria.

Explore solutions
3M™ SoluPrep™ S Sterile Antiseptic Solution, 2% CHG/70% IPA, 67134, Clear, 10.5 mL

Contact a Solventum representative

We're here to help! Our team of representatives can provide you with information and resources to help you. Submit the form below to speak with a Solventum representative to learn more about your options.

Looking for customer support? Visit the customer support page.

Fields marked with an * are required.

 

Solventum will use the information to respond to your request in accordance with our Privacy Policy. 

References

  1. Shambhu, S. The Burden of Health Care Utilization, Cost, and Mortality Associated with Select Surgical ​Site Infections. Joint Commission Journal, volume 50, issue 12, 857-866, December 2024. https://www.jointcommissionjournal.com/article/S1553-7250(24)00259-9/fulltext. ​
  2. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: A meta-analysis of costs ​and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039-2046.​
  3. 3. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization ​in the United States, 2001–2002. J Infect Dis. 2006;193:172-179.​
  4. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus ​aureus infections. N Engl J Med. 2002;346:1871-1877.​
  5. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, deBaere GAJ, Kluytmans JAJW. Nasal ​carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic ​surgery. Infect Control Hosp Epidemiol. 2000;21:319-323.​
  6. Kluytmans JAJW, Mouton JW, Ijzerman EPF, et al. Nasal carriage of Staphylococcus aureus as a major ​risk factor for wound infections after cardiac surgery. J Infect Dis. 1995;171:216-219.​